• Explore /
  • Poster
  • / Concurrent or layered treatment (Tx) with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Concurrent or layered treatment (Tx) with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Neal D. Shore

Carolina Urologic Research Center, Myrtle Beach, SC

Neal D. Shore , Oliver A. Sartor , Cora N. Sternberg , Fred Saad , Bertrand F. TOMBAL , Kurt Miller , Jan Kalinovsky , Xiaolong Jiao , Krishna Tangirala , Celestia S. Higano

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Clinical Trial Registration Number

NCT02043678

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 50)

Abstract #

50

Poster Bd #

B16

Abstract Disclosures

Similar Posters

First Author: Neal D. Shore

First Author: Daniel J. George

First Author: Elena Castro

First Author: Oliver A. Sartor